Results 121 to 130 of about 3,220 (195)

Physiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity

The Journal of Clinical Pharmacology, Volume 66, Issue 2, February 2026.
Abstract Oxcarbazepine (OXC) is a second‐generation antiseizure medication, effective through its active metabolite, 10‐mono‐hydroxy derivative (MHD). OXC is used as adjunctive therapy for focal‐onset and primary generalized tonic–clonic seizures, with recommended dosing based on age and body weight.
Patricia D. Maglalang, Jaydeep Sinha, Victόria Etges Helfer, Andrea Edginton, Kanecia Zimmerman, Chi Dang Hornik, William J. Muller, Mobeen Rathore, Daniel K. Benjamin Jr., Jia‐Yuh Chen, Ravinder Anand, Daniel Gonzalez, the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee   +12 more
wiley   +1 more source

Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics

npj Women's Health
This study employed physiologically based pharmacokinetic (PBPK) modelling to compare the extent of foetal exposure between oral and long-acting injectable (LAI) aripiprazole and olanzapine.
Philip Bediako-Kakari, Mariella Monyo, Shakir Atoyebi, Adeniyi Olagunju   +3 more
doaj   +1 more source

Mechanism‐Based Predictions of Local Tissue and Systemic Exposure for Drug Products Delivered Through the Female Reproductive Tract

The Journal of Clinical Pharmacology, Volume 66, Issue 2, February 2026.
Abstract Effective drug delivery through the female reproductive tract (FRT) presents unique challenges due to the lack of robust predictive models for drug exposure via this route. Addressing this gap, we developed and evaluated a comprehensive whole‐body physiologically based pharmacokinetic (PBPK) model that incorporates anatomical and physiological
Xinnong Li, Thomas Straubinger, Lisa C. Rohan, Sharon L. Achilles, Beatrice A. Chen, Guru Valicherla, Zhongfang Zhang, Mark Donnelly, Eleftheria Tsakalozou, Liang Zhao, Robert Bies   +10 more
wiley   +1 more source

Deconvoluting Gut Versus Liver Cytochrome P450 3A4 Function: Drug Probes, Biomarkers, and Tissue Biopsy

The Journal of Clinical Pharmacology, Volume 66, Issue 2, February 2026.
Abstract Cytochrome P450 3A4 (CYP3A4) is an important drug‐metabolizing enzyme, whose function is impacted by age, sex, body weight, pregnancy, and disease. It is also the site of major drug interactions involving inhibition and induction. Because CYP3A4 is expressed in the intestine and liver, investigators have sought to study its function in both ...
David Rodrigues
wiley   +1 more source

How to integrate in vitro PK/PD information for toxicity prediction [PDF]

, 2009
Predicting drugs' in vivo effects from in vitro testing requires modelling processes that are not reproduced by in vitro systems. The most obvious difference between the two situations is the absence of the absorption, distribution, metabolism, and ...
Bois, Frédéric Y.
core   +1 more source

Development of a Pregnancy‐Specific Physiologically Based Pharmacokinetics (PBPK) Model for Aspirin

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Aspirin is one of the most commonly used medications in pregnancy, particularly for the prevention of hypertensive disorders. Despite aspirin's widespread use in pregnancy for preeclampsia prevention, its pharmacokinetics (PK) across all trimesters remain poorly characterized, complicating optimal dosing recommendations. To develop a pregnancy‐
Ana Collins‐Smith, Ananth Kumar Kammala, Mitch A. Phelps, Xiao Ming Wang, Ramkumar Menon, Maged M. Costantine   +5 more
wiley   +1 more source

Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 583-586, March 2026.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

Managing Drug–Drug Interactions Involving the Non‐Prescription Opioid Loperamide Through Physiologically Based Pharmacokinetic Modeling

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Loperamide is a widely used nonprescription peripherally acting opioid indicated for diarrhea. Loperamide undergoes extensive first‐pass metabolism, primarily by cytochrome (CYP) 3A and CYP2C8, with minor contributions from CYP2B6 and CYP2D6, and intestinal efflux by P‐glycoprotein (P‐gp).
Zhu Zhou, Garrett R. Ainslie, Mengyao Li, Jean Dinh, Maciej J. Zamek‐Gliszczynski, Ping Zhao, Mary F. Paine   +6 more
wiley   +1 more source

A Tutorial on the Development of a Physiologically Inspired PKRO Model for Monoclonal Antibodies

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Modeling and simulations are indispensable tools to describe pharmacokinetics (PK) and pharmacodynamics to support monoclonal antibody (mAb) development. The linear PK of mAbs is commonly described by a 2‐compartment PK model, while the nonlinear PK often observed at low doses is described by target mediated drug disposition (TMDD) models ...
Georgi I. Kapitanov, David Flowers, Diana H. Marcantonio, Timothy R. Lezon, Josh F. Apgar, Fei Hua   +5 more
wiley   +1 more source

A Generalized Minimal PBPK‐PD Model of Bispecific Antibodies: Case Studies and Applications in Drug Development

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Bispecific antibodies (bsAbs), for which each arm binds a distinct molecular target, are developed to engage soluble and cell surface targets in different therapeutic indications. Three key examples of mechanisms of action (MoA) for bsAbs are (1) immune cell engagers that foster immune cell interactions with target cells, (2) bispecifics that ...
Phillip Spinosa, Louis Joslyn, Saroja Ramanujan, Kapil Gadkar, Iraj Hosseini   +4 more
wiley   +1 more source